Cargando…
ALCAM regulates multiple myeloma chemoresistant side population
Drug-resistance is a major problem preventing a cure in patients with multiple myeloma (MM). Previously, we demonstrated that activated-leukocyte-cell-adhesion-molecule (ALCAM) is a prognostic factor in MM and inhibits EGF/EGFR-initiated MM clonogenicity. In this study, we further showed that the AL...
Autores principales: | Wang, Fangfang, Dan, Zhang, Luo, Hongmei, Huang, Jingcao, Cui, Yushan, Ding, Hong, Xu, Juan, Lin, Zhimei, Gao, Yuhan, Zhai, Xinyu, Yang, Yan, Qu, Ying, Zhang, Li, Chen, Fengjiao, Wang, Qiang, Wang, Xin, Feng, Yu, Liu, Ting, Yi, Qing, Niu, Ting, Zheng, Yuhuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831486/ https://www.ncbi.nlm.nih.gov/pubmed/35145058 http://dx.doi.org/10.1038/s41419-022-04556-8 |
Ejemplares similares
-
Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021) -
ALCAM-EGFR interaction regulates myelomagenesis
por: Luo, Hongmei, et al.
Publicado: (2021) -
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5
por: Yang, Yan, et al.
Publicado: (2022) -
BMI1 regulates multiple myeloma-associated macrophage’s pro-myeloma functions
por: Zhang, Danfeng, et al.
Publicado: (2021) -
Liposome-Encapsulated
Melphalan Exhibits Potent Antimyeloma
Activity and Reduced Toxicity
por: Lin, Zhimei, et al.
Publicado: (2022)